ArticleTranslational lung cancer research2026
B cell-driven refractory hemocytopenia in immune checkpoint inhibitor therapy: a report of two cases.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The integration of immune checkpoint inhibitors (ICIs) with chemotherapy has revolutionized lung cancer treatment, yet it amplifies the risk of severe hematologic toxicities. Case Description: We describe two patients with advanced lung cancer who developed life-threatening refractory hemocytopenia following ICIs-chemotherapy, unresponsive to glucocorticoids and hematopoietic growth factors. A striking feature of these cases was the exclusive presence of anti-Sjögren's-syndrome-related antigen A (Ro) (SSA) antibodies in refractory patients, but absent in non-refractory controls. Targeted administration of intravenous immunoglobulin (IVIG) and rituximab was temporally associated with clearance of anti-SSA antibodies and restoration of normal hematopoiesis, raising the hypothesis that aberrant B cell activity may contribute to refractory hemocytopenia in this setting. Conclusions: These observations suggest that anti-SSA antibodies could represent a candidate biomarker for identifying refractory hemocytopenia in early time. These findings support a proposal for routine anti-SSA screening in ICI-related hematologic toxicity to enable timely B cell-targeted management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.